Richard DiFrancesco

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1157613/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Simultaneous determination of cortisol, dexamethasone, methylprednisolone, prednisone, prednisolone, mycophenolic acid and mycophenolic acid glucuronide in human plasma utilizing liquid chromatography–tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 859, 42-51.	1.2	76
2	Quality Assurance Program for Clinical Measurement of Antiretrovirals: AIDS Clinical Trials Group Proficiency Testing Program for Pediatric and Adult Pharmacology Laboratories. Antimicrobial Agents and Chemotherapy, 2004, 48, 824-831.	1.4	64
3	Simultaneous analysis of cyclophosphamide, doxorubicin and doxorubicinol by liquid chromatography coupled to tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 852, 545-553.	1.2	53
4	Effects of Grapefruit Juice on Pharmacokinetic Exposure to Indinavir in HIV-Positive Subjects. Journal of Clinical Pharmacology, 2001, 41, 435-442.	1.0	28
5	Clinical Pharmacology Quality Assurance Program. Therapeutic Drug Monitoring, 2013, 35, 631-642.	1.0	28
6	Determination of lopinavir cerebral spinal fluid and plasma ultrafiltrate concentrations by liquid chromatography coupled to tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2007, 44, 1139-1146.	1.4	20
7	Ultra-performance liquid chromatography tandem mass spectrometry for determination of Direct Acting Antiviral drugs in human liver fine needle aspirates. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1052, 103-109.	1.2	14
8	Development and validation of an assay to measure cannabidiol and Δ9-tetrahydrocannabinol in human EDTA plasma by UHPLC-MS/MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1112, 56-60.	1.2	14
9	Adding value to antiretroviral proficiency testing. Bioanalysis, 2014, 6, 2721-2732.	0.6	12
10	Development and validation of a UPLC–MS/MS method for the simultaneous determination of paritaprevir and ritonavir in rat liver. Bioanalysis, 2016, 8, 1353-1363.	0.6	12
11	Tutorial Reduces Protocol Deviations in Multicenter ACTG Trials with Pharmacology Endpoints. HIV Clinical Trials, 2006, 7, 203-209.	2.0	6
12	Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users. Journal of Pharmaceutical and Biomedical Analysis, 2007, 44, 188-195.	1.4	5
13	Quality Assessment for Therapeutic Drug Monitoring in AIDS Clinical Trials Group (ACTG 5146): A Multicenter Clinical Trial. Therapeutic Drug Monitoring, 2010, 32, 458-466.	1.0	5
14	Paritaprevir and Ritonavir Liver Concentrations in Rats as Assessed by Different Liver Sampling Techniques. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	4
15	Sources of Variability and Accuracy of Performance Assessment in the Clinical Pharmacology Quality Assurance Proficiency Testing Program for Antiretrovirals. Therapeutic Drug Monitoring, 2019, 41, 452-458.	1.0	4
16	Development and validation of a high performance liquid chromatography method to determine nevirapine in plasma in a resource-limited setting. African Journal of Laboratory Medicine, 2019, 8, 880.	0.2	3
17	Two decades (1998 to 2018) of collaborative human immunodeficiency virus clinical pharmacology capacity building in a resource constrained setting. Cost Effectiveness and Resource Allocation, 2021, 19, 73.	0.6	3
18	A Quality Assurance Program for AIDS Clinical Trials Group Pharmacology studies. Quality Assurance Journal, 2005, 9, 22-30.	0.1	0

# ARTICLE		IF	CITATIONS
19 Cross-validatic resource-limite	n of a high-performance liquid chromatography nevirapine plasma assay in a d setting in Zimbabwe. African Journal of Laboratory Medicine, 2021, 10, 1264.	0.2	0